Drug Trial Radar · NCT02147158
A Study of the Efficacy and Safety of Ulipristal Acetate Intermittent Treatment for Abnormal Uterine Bleeding Associated With Leiomyomas
Last checked: Nov 20, 2026Latest source record: Jun 4, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
432
Actual
Start
Jan 29, 2014
Primary completion
Nov 24, 2016
Study completion Nov 24, 2016
Sponsor
- Lead sponsor
- AllerganAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- May 26, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the superiority of ulipristal acetate versus placebo for the treatment of abnormal uterine bleeding associated with uterine fibroids
Conditions
- Leiomyoma
- Uterine Hemorrhage
Interventions
Ulipristal acetate (UPA)Drug
Ulipristal acetate (UPA) tablet.
PlaceboDrug
Matching placebo tablet.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Absence of Bleeding During the Last 35 Consecutive Days on Treatment in Treatment Course 1Time frame: Last 35 consecutive days on treatment in the 12-Week Treatment Course 1
- Time to Absence of Bleeding on Treatment During Treatment Course 1Time frame: From first dose up to the end of the 12-Week Treatment Course 1
Locations
63 sites in 2 countries. Site status is shown where the registry gives one.
Watson Investigational Site 138
Mesa, Arizona
Watson Investigational Site 147
Phoenix, Arizona
Watson Investigational Site 106
Scottsdale, Arizona
Watson Investigational Site 124
Tucson, Arizona
Watson Investigational Site 155
Little Rock, Arkansas
Watson Investigational Site 155
Encino, California
Watson Investigational Site 157
Hawaiian Gardens, California
Watson Investigational Site 134
La Mesa, California
Watson Investigational Site 127
San Diego, California
Watson Investigational Site 151
San Diego, California
Watson Investigational Site 159
Denver, Colorado
Watson Investigational Site 131
Clearwater, Florida
Watson Investigational Site 135
Miramar, Florida
Watson Investigational Site 132
North Miami, Florida
Watson Investigational Site 161
Orlando, Florida
Watson Investigational Site 123
Plantation, Florida
Watson Investigational Site 112
Sarasota, Florida
Watson Investigational Site 102
Wellington, Florida
Watson Investigational Site 101
West Palm Beach, Florida
Watson Investigational Site 160
Atlanta, Georgia
Watson Investigational Site 103
Sandy Springs, Georgia
Watson Investigational Site 117
Savannah, Georgia
Watson Investigational Site 113
Champaign, Illinois
Watson Investigational Site 119
Schaumburg, Illinois
Watson Investigational Site 162
Brownsburg, Indiana
Watson Investigational Site 104
Granger, Indiana
Watson Investigational Site 150
Covington, Louisiana
Watson Investigational Site 130
Metairie, Louisiana
Watson Investigational Site 116
New Orleans, Louisiana
Watson Investigational Site 108
Las Vegas, Nevada
Watson Investigational Site 107
Las Vegas, Nevada
Watson Investigational Site 111
Lawrenceville, New Jersey
Watson Investigational Site 158
Moorestown, New Jersey
Watson Investigational Site 115
Albuquerque, New Mexico
Watson Investigational Site 155
The Bronx, New York
Watson Investigational Site 126
Durham, North Carolina
Watson Investigational Site 128
Greensboro, North Carolina
Watson Investigational Site 145
New Bern, North Carolina
Watson Investigational Site 146
Raleigh, North Carolina
Watson Investigational Site 118
Winston-Salem, North Carolina
Showing 40 of 63 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.